Skip to main content
PMC home page
The British Journal of General Practice logoLink to The British Journal of General Practice
. 1995 May;45(394):239–244.

Continuous and on demand use of bronchodilators in patients with non-steroid dependent asthma and chronic bronchitis: four-year follow-up randomized controlled study.

C P van Schayck 1, E Dompeling 1, C L van Herwaarden 1, H Folgering 1, R P Akkermans 1, P J van den Broek 1, C van Weel 1
PMCID: PMC1239228  PMID: 7619569

Abstract

BACKGROUND. A previous two-year study of continuous and on demand bronchodilator therapy in patients with moderate asthma and chronic bronchitis showed a deterioration in lung function in those on continuous therapy. AIM. A two-year follow-up study was undertaken of patients who had been shown in the previous study to have non-steroid dependent (mild) asthma and chronic bronchitis, in order to investigate the effect of continuous and on-demand treatment with bronchodilator therapy. METHOD. Patients for the study were drawn from 29 general practices in the catchment area of the University of Nijmegen, the Netherlands. A total of 83 patients (27 with asthma and 56 with chronic bronchitis) were selected from a group of 160 patients who had completed the previous two-year bronchodilator trial. During these first two years the selected subjects had been shown to be non-steroid dependent (no rapid decline in lung function and a low number of exacerbations of their condition per year), and they were followed up for another two years of treatment with bronchodilator therapy. At the start of the four-year study, patients were randomly assigned to one of two parallel treatment groups: continuous treatment (dry powder inhalations of either salbutamol 1600 micrograms or ipratropium bromide 160 micrograms daily) or treatment on demand (only during exacerbations or periods of dyspnoea). Outcome parameters were the annual decline in lung function, changes in peak flow rate, bronchial hyper-responsiveness, exacerbation rate, respiratory symptoms and reported health. RESULTS. After correction for possibly confounding variables and for regression to the mean, the decline in lung function was 49 ml year in patients taking bronchodilators continuously and 51 ml year in patients using bronchodilators on demand, irrespective of the drug use. Continuously treated patients, whether suffering from asthma or chronic bronchitis, did not differ from patients treated on demand with respect to mean morning peak flow rate, diurnal (and week to week) variation of the peak flow rate, bronchial hyper-responsiveness, exacerbation rate and reported health. There was no difference between the long-term effects of salbutamol and ipratropium. CONCLUSION. Continuous use of bronchodilators over four years in patients with non-steroid dependent asthma or chronic bronchitis does not increase the decline in lung function which had been observed previously in patients with moderate asthma or chronic bronchitis during two years of continuous treatment with bronchodilators.

Full text

PDF
239

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Boman G., Bäcker U., Larsson S., Melander B., Wåhlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis. 1983 Aug;64(6):405–415. [PubMed] [Google Scholar]
  2. Burrows B., Lebowitz M. D. The beta-agonist dilemma. N Engl J Med. 1992 Feb 20;326(8):560–561. doi: 10.1056/NEJM199202203260809. [DOI] [PubMed] [Google Scholar]
  3. Busse W. W., Sosman J. M. Isoproterenol inhibition of isolated human neutrophil function. J Allergy Clin Immunol. 1984 Mar;73(3):404–410. doi: 10.1016/0091-6749(84)90416-0. [DOI] [PubMed] [Google Scholar]
  4. Cockcroft D. W., Killian D. N., Mellon J. J., Hargreave F. E. Bronchial reactivity to inhaled histamine: a method and clinical survey. Clin Allergy. 1977 May;7(3):235–243. doi: 10.1111/j.1365-2222.1977.tb01448.x. [DOI] [PubMed] [Google Scholar]
  5. Crane J., Pearce N., Flatt A., Burgess C., Jackson R., Kwong T., Ball M., Beasley R. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet. 1989 Apr 29;1(8644):917–922. doi: 10.1016/s0140-6736(89)92505-1. [DOI] [PubMed] [Google Scholar]
  6. Davis C. E. The effect of regression to the mean in epidemiologic and clinical studies. Am J Epidemiol. 1976 Nov;104(5):493–498. doi: 10.1093/oxfordjournals.aje.a112321. [DOI] [PubMed] [Google Scholar]
  7. Dompeling E., Van Grunsven P. M., Van Schayck C. P., Folgering H., Molema J., Van Weel C. Treatment with inhaled steroids in asthma and chronic bronchitis: long-term compliance and inhaler technique. Fam Pract. 1992 Jun;9(2):161–166. doi: 10.1093/fampra/9.2.161. [DOI] [PubMed] [Google Scholar]
  8. Dompeling E., van Grunsven P. M., Molema J., Verbeek A. L., van Schayck C. P., van Weel C. Early detection of patients with fast progressive asthma or chronic bronchitis in general practice. Scand J Prim Health Care. 1992 Jun;10(2):143–150. doi: 10.3109/02813439209014052. [DOI] [PubMed] [Google Scholar]
  9. Dompeling E., van Schayck C. P., Folgering H., van den Hoogen H. J., van Weel C. Accuracy, precision and linearity of the portable flow-volume meter Microspiro HI-298. Eur Respir J. 1991 May;4(5):612–615. [PubMed] [Google Scholar]
  10. Dompeling E., van Schayck C. P., van Grunsven P. M., van Herwaarden C. L., Akkermans R., Molema J., Folgering H., van Weel C. Slowing the deterioration of asthma and chronic obstructive pulmonary disease observed during bronchodilator therapy by adding inhaled corticosteroids. A 4-year prospective study. Ann Intern Med. 1993 May 15;118(10):770–778. doi: 10.7326/0003-4819-118-10-199305150-00003. [DOI] [PubMed] [Google Scholar]
  11. Juniper E. F., Kline P. A., Vanzieleghem M. A., Ramsdale E. H., O'Byrne P. M., Hargreave F. E. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis. 1990 Oct;142(4):832–836. doi: 10.1164/ajrccm/142.4.832. [DOI] [PubMed] [Google Scholar]
  12. McGowan S. E., Hunninghake G. W. Neutrophils and emphysema. N Engl J Med. 1989 Oct 5;321(14):968–970. doi: 10.1056/NEJM198910053211410. [DOI] [PubMed] [Google Scholar]
  13. Page C. P. One explanation of the asthma paradox: inhibition of natural anti-inflammatory mechanism by beta 2-agonists. Lancet. 1991 Mar 23;337(8743):717–720. doi: 10.1016/0140-6736(91)90289-2. [DOI] [PubMed] [Google Scholar]
  14. Schrier A. C., Dekker F. W., Kaptein A. A., Dijkman J. H. Quality of life in elderly patients with chronic nonspecific lung disease seen in family practice. Chest. 1990 Oct;98(4):894–899. doi: 10.1378/chest.98.4.894. [DOI] [PubMed] [Google Scholar]
  15. Sears M. R., Taylor D. R., Print C. G., Lake D. C., Li Q. Q., Flannery E. M., Yates D. M., Lucas M. K., Herbison G. P. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990 Dec 8;336(8728):1391–1396. doi: 10.1016/0140-6736(90)93098-a. [DOI] [PubMed] [Google Scholar]
  16. Spitzer W. O., Suissa S., Ernst P., Horwitz R. I., Habbick B., Cockcroft D., Boivin J. F., McNutt M., Buist A. S., Rebuck A. S. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med. 1992 Feb 20;326(8):501–506. doi: 10.1056/NEJM199202203260801. [DOI] [PubMed] [Google Scholar]
  17. van Schayck C. P., Dompeling E., van Herwaarden C. L., Folgering H., Verbeek A. L., van der Hoogen H. J., van Weel C. Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. BMJ. 1991 Dec 7;303(6815):1426–1431. doi: 10.1136/bmj.303.6815.1426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. van Schayck C. P., Dompeling E., van Weel C., Folgering H., van den Hoogen H. J. Accuracy and reproducibility of the Assess peak flow meter. Eur Respir J. 1990 Mar;3(3):338–341. [PubMed] [Google Scholar]
  19. van Schayck C. P., Folgering H., den Otter J. J., Tirimanna P., van Weel C. Does the continuous use of bronchodilators mask the progression of asthma or chronic bronchitis? Fam Pract. 1992 Dec;9(4):397–404. doi: 10.1093/fampra/9.4.397. [DOI] [PubMed] [Google Scholar]
  20. van Schayck C. P., Rutten-van Mölken M. P., van Doorslaer E. K., Folgering H., van Weel C. Two-year bronchodilator treatment in patients with mild airflow obstruction. Contradictory effects on lung function and quality of life. Chest. 1992 Nov;102(5):1384–1391. doi: 10.1378/chest.102.5.1384. [DOI] [PubMed] [Google Scholar]
  21. van Schayck C. P., van Weel C., Folgering H., Verbeek A. L., van Herwaarden C. L. Treatment of patients with airflow obstruction by general practitioners and chest physicians. Scand J Prim Health Care. 1989 Oct;7(3):137–142. doi: 10.3109/02813438909087230. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of General Practice are provided here courtesy of Royal College of General Practitioners

RESOURCES